Rebirth of the God-level Xueba

After looking at the information all night, Van Lundin pretended to be very confident and came to Hua Rui's laboratory. .

He is a medicinal chemist and biologist with academic background, but the more so, the more he understands the challenges he may face, just like all medicinal chemists and biologists face when they first encounter a new project Like the challenge, Van Lundin knew that he would face a vast array of biological literature and related basic principles.

When researchers in any company are preparing to make a certain drug, the first thing they need to do is to consult a huge amount of literature.

In the case of Zelikon, researchers usually fill up three rooms with materials, read them all, and make notes.

If you are going to ask the company to spend millions of dollars to start a project, and expect to spend hundreds of millions of dollars, then you'd better prepare for it.

Regardless of how relaxed he was when he talked to Arnold, Van Lentin still dared to see Yang Rui after staying up all night seriously.

"Mr. Yang Rui." Van Lundin came to the Huarui laboratory and greeted the Chinese researchers very politely.

Van Lunding has read Yang Rui's articles, and Van Lunding has also studied the design of coenzyme q10 made by Yang Rui.

Although he didn't want to admit it, Van Lundin originally joined the industry because of his poor research talent. Not to mention Yang Rui, who is the top level in academia, or even an ordinary big cow, and Van Lundin has to pay attention to his words.

He didn't want to be caught in the wrong place by Yang Rui, so as to be laughed at.

Unfamiliarity with deferiprone is a key flaw that Van Lundin thinks. Therefore, after saying hello, Van Lundin hurriedly said: "I heard that you are not clear about the process of new drug research and development. I have participated in an immature project before. I hope I can help."

"Of course you can help, come in quickly. We just need you." Yang Rui greeted warmly. What he needs most now is a guide, even if he is a blind person, as long as he can hit the right way with a cane, Yang Rui is very happy.

Van Lundin was a little guilty and asked with some contentment: "Which step did you do?"

"We are still synthesizing more active substances. I think it would be better to have a few more backups." Yang Rui didn't have the need to hide.

Van Lundin slowly entered the state and said: "That's right, the more active substances, the greater the chance of getting the final product."

Ordinary small companies generally only need to prepare two or three active substances. Their goal is not to make new drugs, but to sell them to large companies after the first phase of animal experiments or clinical trials.

Large pharmaceutical companies prepare more active substances, often more than 20 kinds. Companies such as Pfizer often prepare more than 50 active substances. The final result, such as Pfizer and others, often is that the backup compound and the main attack compound pass the fda audit together, thus turning one medicine into two medicines.

This is a winner-takes-all industry. Most small companies cannot hold on for 36 months. Large pharmaceutical companies are not always able to get what they want. Super pharmaceutical companies such as Pfizer face the problem of high costs. The average cost of developing a new drug is 700 million U.S. dollars, far exceeding the industry average of 200 million U.S. dollars.

Compared with generic drugs that often cost only a few million yuan, the depth of the bottomless pit of original drugs cannot be measured.

Van Lundin decided to persuade Yang Rui to do a few more active substances first, then to open a few more animal experiments, and then another set of clinical trials. If no results are achieved at this point, the average pharmaceutical company will be ruined.

And the chance of failing to score is very high.

"The project team I used to work in was mainly to develop antibiotics, but unfortunately it failed. If I still retain the experience, it is to give a relatively generous estimate of the possible problems in the experiment." Van Lundin did not go to iron. Ketone continues, but only talks about his own experience, so as not to show his cowardice.

Yang Rui agreed: "Fan Yu is very useful. Which step did you do?"

With exactly the same problem as Arnold, Van Lundin said: "The second phase of the clinical trial was not successful."

"Unfortunately."

"It is related to our initial plan. You know, antibiotics are actually a relatively easy to develop drug. Because the effectiveness of the drug can be tested in vitro, no one thought that the second phase of the clinical trial would fail." Van Lundin said and introduced Some situations within the project team.

Yang Rui, Wei Zhenxue and others nodded as they listened. This is indeed a rare experience.

After a while, Wei Zhenxue asked strangely: "You just said that the effectiveness of antibiotics can be understood in the laboratory without human testing. Before you do animal experiments, you should know whether it is effective or not. , How can the second phase fail?"

"We did not predict that it is a temperature-sensitive compound. Once a patient develops a high fever, its effectiveness will be greatly reduced." Van Lundin shrugged, his face a little embarrassed.

Wei Zhenxue laughed without hesitation.

This is indeed a stupid way to fail.

Huang Mao said comfortingly: "There is no way you are lucky."

Van Lundin’s embarrassment passed quickly, and then he said: “There are too many problems encountered in clinical trials. Although I want to admit that it is a factor of luck, compared with the successful project team, I think it is our lack of preparation in the early stage.”

"Oh, what do you mean?"

"First of all, there is no backup compound." Van Lundin said that the compound facing the same target but different structure, such as deferoxamine and deferiprone, is such a relationship. This hierarchical structure is more powerful than multiple active substances. .

Yang Rui shook his head: "We can't afford it."

Of course Van Lundin knew that they couldn't afford it, and it wasn't a small company that could afford it.

Van Lundin nodded: "Our project team also wanted to save this money back then to increase the success rate of a compound. I have to say that we were very optimistic about that compound back then. No one wanted to get it. Eventually we will encounter temperature. Sensitive situation."

"Didn't you experiment in advance?" Huang Mao asked.

"The performance of in vitro experiments is not obvious. The environment in the human body obviously increases its sensitivity."

"This is unexpected." Yang Rui nodded his head. He was also worried about this kind of thing. In other words, every project director was worried about this unexpected thing. People are not gods. Any exploration into new areas. , We must pray for good luck, and when bad luck is all around, everyone will rush to the street.

"Yes, so, if the second phase of the clinical trial did not pass, our project team was disbanded." Van Lundin paused, and then said: "In fact, there are many reasons for failure. The lack of backup drugs is just one of them. We prepared in the early stage. Too little active material is also a big problem."

"How many active substances did you synthesize?" Wei Zhenxue naturally followed his words.

"Six types. Our project team is not highly valued, because it has been reorganized once, and its competitiveness is not as good as other projects~www.NovelMTL.com~ so it is relatively tight, synthetic active substances are less, and as a result, animal experiments have passed fewer active substances. When it comes to the first phase of the clinical trial, there is no choice. There are problems in the second phase of the clinical trial, and there is no backup, so the project can only be declared as a failure..." Van Lundin is telling the truth, there is no lie.

There are few synthetic active substances, which is the disadvantage. Although the six active substances are slightly more than the synthesis of small companies, they are pitiful enough. Normal small pharmaceutical companies don't want to pass clinical phase two or even phase three, and their capital does not allow them to invest such a huge amount.

Wei Zhenxue's face changed slightly and asked, "You have prepared a total of 6 active substances, all of them?"

Van Lunding thought he was scared to Wei Zhenxue, and quickly explained: "We have been doing this for nearly a year, and we have exhausted everyone. At that time, our synthesis work was not smooth, so we finally prepared 6 kinds. If your goal is to make a finished drug of deferiprone, I think the standard for the six active substances is not high."

"Of course not high." Wei Zhenxue murmured.

"En?" Van Lundin didn't understand much.

"We have already made 12 kinds, which happens to be twice as much as you said." Wei Zhenxue curled his lips and said, "Yang Rui is still going to continue doing it."

"I agree with your point of view. The preliminary preparation must be sufficient." Yang Rui does not understand pharmaceuticals, but he knows the research direction of deferiprone. Therefore, a large number of active substances with the structure of deferiprone are made to cover as comprehensively as possible. The most correct choice.

Van Lundin prepared a word of persuasion, and he just started to use it...It is said that his goal has been achieved, but looking at Yang Rui's confident expression and the positive atmosphere in the laboratory, Van Lundin felt inexplicably sad.